Skip to main content
KREDKRED
039200KOSDAQ

Oscotec

37,700
-2,000 (-5.04%)

Price chart

  • MA5
  • MA20
  • MA60

Adjusted prices rescale past bars with coefficients taken from the base prices the exchange itself published, correcting for corporate actions such as stock splits and reverse splits. Cash dividends are not reflected, and the risk measures on this page never use these adjusted figures.

Market capitalizationKRW 1T

Each day's close multiplied by the listed share count of this share class alone, sampled weekly. It is the figure for this issue only, not a combined total across common and preferred shares.

Overview

Summary

Oscotec is a biotechnology company established on December 8, 1998. The company is headquartered in Seongnam, Gyeonggi-do and is listed on the KOSDAQ market.

The company focuses on the development of synthetic new drugs for diseases such as arthritis and cancer. Its business segments include synthetic drug development, functional materials and related products, and dental bone graft materials. It supplies functional materials for health supplements and provides bone graft products to dental clinics.

Business overview as filed

당사는 연구중심의 신약개발 및 바이오 기업으로서 창사 이래 관절염, 항암제 등과 관련된 질병의 합성신약개발에 주력해 왔으며, 신약개발과정에서 얻어진 여러 가지 연구 산물과 축적된 지식을 기능성 소재 및 관련제품, 골이식재 등의 사업화를 통해 차별화된 사업모델을 구축해 왔습니다. 현재, 당사는 연구개발전문 바이오의약품 기업으로의 확장을 위해 기술도입 계약 체결을 통해 공동연구 개발 중에 있습니다.이러한 사업모델에 따라 당사는 주력인 1)신약개발사업(합성신약) 2)기능성 소재 및 관련 제품사업, 3)치과용 골이식재 사업을 영위하고 있습니다.

현재 신약개발사업은 2종의 합성 신약 후보물질에 대하여 임상시험을 진행하고 있습니다. 국내제약사에 기술이전한 표적항암제 폐암 치료 물질은 한국 식약처 및 미국 FDA에서 단독 또는 병용 1차 치료제로 승인을 받았습니다. 골이식재 사업 및 차폐막 사업은 주로 치과를 대상으로 한 제품으로, 우수한 가격경쟁력을 확보하고 있으며 해외 시장 진출도 고려하고 있습니다.기능성 소재 및 관련제품은 주로 건강기능식품의 소재로 판매되고 있으며, 신약 연구개발에 대한 축적된 기술력과 노하우를 바탕으로 연구개발 된 제품이라는 점에서 여타 업체의 제품들에 비해 효능과 과학적인 연구결과에 있어 비교우위를 보이고 있습니다.

Company overview

1. 연결대상 종속회사 개황(연결재무제표를 작성하는 주권상장법인이 사업보고서, 분기ㆍ반기보고서를 제출하는 경우에 한함)연결대상 종속회사 현황(요약)

1-1. 연결대상회사의 변동내용

2. 회사의 법적ㆍ상업적 명칭당사의 명칭은 "주식회사 오스코텍"이고, 영문명은 "OSCOTEC Inc.."입니다

3. 설립일자당사는 1998년 12월 08일 "주식회사 오스코텍"으로 설립되었습니다.

4. 본사의 주소, 전화번호, 홈페이지 주소본사의 주소 : 경기도 성남시 분당구 대왕판교로 700 A-901(삼평동,코리아바이오파크)전화번호 : 031-628-7613홈페이지 : http://www.oscotec.com

5. 중소기업 등 해당 여부

6. 주요 사업의 내용(주요제품 및 서비스 등을 포함한다) 및 향후 추진하려는 신규사업에 관한 간략한 설명당사는 신약개발전문 생명공학기업으로서 창사 이래 관절염, 항암제 등과 관련된 질병의 합성신약개발에 주력해 왔으며, 신약개발과정에서 얻어진 여러 가지 연구 산물과 축적된 지식을 기능성 소재 및 관련제품, 골이식재 등의 사업화를 통해 차별화된 사업모델을 구축해 왔습니다. 한편 당사는 연구개발전문 바이오의약품 기업으로의 확장을 위해 기술도입 계약 체결을 통해 공동연구 개발 중에 있습니다. 이러한 사업모델에 따라 당사는 주력인 1)신약개발사업(합성신약) 2)기능성 소재 및 관련 제품사업, 3)치과용 골이식재 사업을 영위하고 있습니다.7. 신용평가에 관한 사항- 해당사항 없습니다.

8. 회사의 주권상장(또는 등록ㆍ지정) 및 특례상장에 관한 사항

Transcribed verbatim from the sentences the filer wrote in the fiscal 2025 business report (received 2026.03.19), tables and figures omitted.

  • The summary is written separately from the filed text and is not the filer's wording, so it may phrase things differently from or omit parts of the original, which is shown alongside for checking.
  • The company introduction reproduces the sentences the filer wrote in its business report, with tables, figures and the sentences that point to other sections of the report omitted, and the accuracy of their content has not been separately verified.

VaR

4.62%
[3.19%, 6.67%] · As of 2026-10-02
VaR by window

The headline's measure for each of the three windows on one scale, the dot being the estimate and the bar its interval. The windows are nested and share their observations, so the three readings are not three independent measurements. The selected window is highlighted.

Daily return distribution

The issue's daily returns over the chosen window counted into equal-width bins. The vertical lines mark the VaR and cVaR above on the loss side. The published VaR sample applies exclusion rules for halts and first sessions that this raw daily series does not, so the bars and the marks can differ slightly at the edges.

Drawdown

Deepest drawdown 54.8% (2026-07-14). How far below its previous peak the issue stood each day over the chosen window, a description of the path already travelled.

If these numbers are unfamiliarThere is a guide that walks through VaR, cVaR and annualized volatility in plain language.Read the guide

Characteristic line

0.68
Beta [0.54, 0.82] · KOSDAQ150 · As of 2026-10-08
Intercept
-0.010%[-0.424%, +0.403%]
R squared
0.27
Observations
252
Trading-time corrected beta
0.65[0.41, 0.89]
252-day rolling beta

A 252-day window rolled one day at a time over the longest daily span of the characteristic line. It shows when the beta against the KOSDAQ150 and the annualized volatility of the issue's excess return rose and fell, and unlike the headline figures above it carries no interval.

252-day rolling annualized volatility

Each point is one period's index excess return and issue excess return, and the line is the regression fitted to those points. The risk-free rate is the certificate of deposit rate.

Financials

20152016201720182019202020212022202320242025TTM
RevenueKRW 100M1833639187444353951503409981,442
Revenue growth%—-80.629.98378.51-76.64895.09-91.0229.71-2.20586.89193.58—
Operating incomeKRW 100M7-17-5862-19916-281-286-327-27521897
Operating income growth%—-353.72——-421.42—-1,877.78—————
Net incomeKRW 100M4-44-6443-250-20-286-278-285-165441,004
Net income growth%—-1,310.86——-683.49———————
Attributable to ownersKRW 100M4-36-5935-224-44-263-244-2439523941
Attributable to minoritiesKRW 100M-0-8-58-2523-23-33-42-252164
Operating margin%3.74-48.95-148.5433.03-454.533.64-719.93-565.71-659.58-8.0452.1762.23
Net margin%1.98-123.83-163.2322.88-571.43-4.71-732.56-548.63-575.44-4.6854.4869.66
ROE%1.51-13.85-27.577.50-43.74-8.21-91.10-19.94-24.540.6928.8743.56
ROA%0.73-10.78-15.746.09-34.48-2.68-58.39-19.32-21.49-0.9323.6737.59
Debt ratio%83.8941.9158.0535.9833.1633.4557.0017.9939.9729.0323.0219.21
Current ratio%140.31196.84252.00364.56383.39353.62117.64580.75293.92406.04510.46609.27
Quick ratio%91.85187.55244.45358.19376.35346.57109.32573.93289.04400.96505.81603.84
Reserve ratio%———————————982.76
OCF conversion%177.59——-118.69——————15.26—
Receivable daysdays—488.0446.6225.7825.7107.91,207.491.0143.0200.4224.8—
Inventory daysdays—1,387.7186.0141.2175.8203.5214.9222.7266.8284.4336.2—
Payable daysdays—553.3102.5129.7141.4842.51,043.0544.6567.5642.91,565.8—
Cash conversion cycledays—1,322.4530.0237.2860.0-531.2379.4-230.9-157.7-158.2-1,004.8—
EPSKRW15-173-240153-890-155-866-763-635231,3682,459
PERx———147.71—————1,058.7033.0414.74
BPSKRW—1,0277801,6991,7561,8179543,3472,6043,3404,7395,644
PBRx—6.9621.1013.3013.7236.1138.355.178.857.299.546.42
Dividend per shareNot applicableNot applicableNot applicableNot applicableNot applicableNot applicableNot applicableNot applicableNot applicableNot applicableNot applicableNot applicable

Consolidated basis

Profit flowKRW 100M

Revenue
998
Gross profit
979
Cost of sales
19
Operating income
521
Other
276
SG&A expenses
182
Non-operating income
7
Profit before tax
528
Income tax benefit
16
Net income
544

This diagram traces where revenue goes at each step on its way to net income, using the filed amounts as they are. The non-operating result is taken as the difference between profit before tax and operating income and is shown as income or expense by its sign, and whatever a step's items leave unexplained is shown separately as other.

Revenue compositionKRW 100M

Margins%

Cash flow by activityKRW 100M

Balance sheet compositionKRW 100M

Debt ratio%

The left bar splits assets into current and non-current and the right bar splits the financing of those assets into liabilities and equity, so the two bars stand at the same height.

Quarterly resultsKRW 100M

Year-on-year growth%

Each quarterly bar is that quarter's three months and is never mixed with an annual figure. The growth rate is computed only where the same quarter a year earlier is also shown here, and is left blank when the base was a loss.

Cash conversion cycledays

Inventory days and receivable days stack upward, payable days hang downward, and the cash conversion cycle they net to is drawn as the line. Each day count uses the average balance with the prior year, so the oldest year is not drawn. A day count whose line was not filed is left out, and the cycle is shown only for years that carry all three.

Owners' net margin%

Asset turnoverx

Financial leveragex

ROE%

ROE is the product of the owners' net margin, asset turnover and financial leverage. All three use period-end balances as denominators, and profit and equity are on the owners' basis, so the product matches the ROE in the table.

Financial statements

Balance sheet

20152016201720182019202020212022202320242025
495408*4057037247644901,4371,3261,7082,299
226121149186180191178219379384430
269288*2575175445723121,2189471,3241,868

Income statement

20152016201720182019202020212022202320242025
183363918744435395150340998
7-17*-5862-19916-281-286-327-27521
3-49*-6452-22713-286-280-323-11528
4-44*-6443-250-20-286-278-285-16544
Basic earnings per shareKRW15-173*-240153-890*-155-866-763-635231,368
Diluted earnings per shareKRW14-173*-240153-890*-155-866-763-635231,368
6-40*-6351-248-32-268-269-285-22557

Cash flow statement

20152016201720182019202020212022202320242025
Net incomefrom the income statement4-44-6443-250-20-286-278-285-16544
Total adjustments to operating cash flowcomputed31027-94250-1581981464-244-461
6-34*-37-510-179-88-264-220-26083
-10459*28-7918-24468-996134-3-41
101-13179193208-10631,203111303-19
Cash at beginning of periodKRW 100M182133197264492581065580131
2133197264492581065580131152
Net change in cash and cash equivalentsKRW 100M31216467229-43448-51245221

In the latest fiscal year cash generated by operations covered both investing outflows and financing outflows.

A year whose own filing is absent is filled from the restated comparative in the following filing, and is marked as such. Operating indicators outside the statements, such as order backlogs, and audit opinions are not covered here, and per-share figures follow the filed values without retroactive adjustment for share splits.

Transcribed verbatim from the sentences the filer wrote in the fiscal {year} business report (received {date}), with tables, figures and cross-references to other sections omitted.

The newest annual filing shown was received on 2026.03.19.

Audit opinion

Fiscal yearOpinionAuditorFiscal year end
2025적정의견Term 28인덕회계법인2025-12-31
2024적정의견Term 27인덕회계법인2025-12-31
2023적정의견Term 26인덕회계법인2025-12-31
2022적정Term 25삼덕회계법인2022-12-31
2021적정Term 24삼덕회계법인2022-12-31
2020적정Term 23삼덕회계법인2022-12-31
2019적정Term 22인덕회계법인2019-12-31
2018적정Term 21인덕회계법인2019-12-31
2017적정인덕회계법인2019-12-31
2016적정Term 18인덕회계법인2016-12-31
2015적정Term 17인덕회계법인2016-12-31

The auditor's name and the opinion are transcribed verbatim from the filed audit report, and the wording follows the filer. A fiscal year shown twice means the filing carried two entries that the source does not distinguish.

Korean audit opinions come in four kinds, where an unqualified opinion (적정) finds the statements fairly presented, a qualified opinion (한정) does so except for a stated matter, an adverse opinion (부적정) finds them not fairly presented, and a disclaimer of opinion (의견거절) means the auditor could not obtain enough evidence to form a view.

Valuation

Valuation multiplesx

PER and PBR divide each period's closing price by the per-share figure filed for that same period, and a loss period is left blank. The quarterly view is a multiple of quarterly EPS.

PER bandKRW

The price is the adjusted close and each band line multiplies the EPS of the latest completed fiscal year by a fixed multiple. The previous year's EPS stays in force until the next fiscal year ends, and the multiples divide the range between the lowest and highest annual PER on record into equal steps.

Valuation models

Five models priced under one set of assumptions, set beside the current price, with how each has moved by fiscal year.

Assumptions

Risk-free rate10-year treasury yield · 2026-10-084.40%
BetaDaily 5Y0.76
%
%
Cost of equity8.21%
Weighted average cost of capital—
Initial growth28.9%
Effective tax rate0.0%
Base fiscal year2025
Current priceKRW37,700

The risk premium and the terminal growth rate are adjustable assumptions, and the rest follow from the data and the formulas.

ModelModel priceKRWVersus current price
Gordon growth modelNo dividend
Dividend discount model DDMNo dividend
Discounted cash flow FCFFNo cash flow lines
Discounted cash flow FCFENo cash flow lines
Residual income model RIM41,208+9.3%
The table prices the newest fiscal year's accounts at today's treasury yield and the current price.

Dividend and residual income familyKRW

Discounted cash flow familyKRW

Each fiscal year's figures use that year's accounts and the treasury yield at its period end, with beta held at its current value, and splits or par changes are restated to the current share basis.

How the figures are calculated

Each model's formula is shown in symbols and then with this issue's own numbers substituted, step by step. Changing a value in the assumptions panel changes the numbers here too. Firm-level amounts are in hundred million won and per-share values in won.

Cost of equity

r=rf+β×ERPr = r_f + \beta \times \mathit{ERP}

r = 4.40% + 0.76 × 5.00% = 8.21%

Initial growth

g1=max⁡{ROE×(1−payout), 0},gt=g1+(gT−g1) t−1N−1g_1 = \max\{\mathit{ROE} \times (1 - \text{payout}),\,0\},\qquad g_t = g_1 + (g_T - g_1)\,\frac{t-1}{N-1}

g_1 = max(28.87% × (1 − 0.00%), 0) = 28.87%

Growth starts at this value in the first year and falls by equal steps each year to reach the terminal rate in the fifth

Residual income model RIM

P0=B0+∑t=1NRIt(1+r)t+RIN(1+gT)(r−gT) (1+r)N,RIt=(ROE−r) Bt−1P_0 = B_0 + \sum_{t=1}^{N} \frac{\mathit{RI}_t}{(1+r)^t} + \frac{\mathit{RI}_N (1+g_T)}{(r - g_T)\,(1+r)^N},\qquad \mathit{RI}_t = (\mathit{ROE} - r)\,B_{t-1}

B_0 = 4,739 KRW, ROE = 28.87%, payout ratio = 0.00%, r = 8.21%, g_T = 2.00%

YearOpening book valueEarningsEquity chargeResidual incomeDiscount factorPresent value
14,7391,3683899790.9241905
26,1071,7635021,2610.85391,077
37,8702,2726471,6260.78911,283
410,1422,9288332,0950.72921,528
513,0713,7731,0742,7000.67391,819
Terminal value44,3080.673929,857

P_0 = 4,739 + 6,611 + 29,857 = 41,208 KRW

The cost of equity is the risk-free rate plus beta times the equity risk premium. Initial growth is the newest fiscal year's return on equity times its retention ratio, floored at zero, and falls by equal steps from that value in the first year to the terminal rate in the fifth. Only the Gordon model grows at the terminal rate from the start. Discounted cash flow starts from operating cash flow less capital expenditure, where FCFF adds after-tax interest paid and discounts at the weighted average cost of capital, and FCFE adds net borrowing and discounts at the cost of equity. The residual income model adds to book value per share the present value of earnings above the equity charge.

Other issues on the same market

Neighbours in the market capitalisation order.

See the full KOSDAQ list